Few corners of the market have been as punishing as ASX tech shares over the past year.
The S&P/ASX 200 Information Technology Index (ASX: XIJ) has been hit hard by a collapse in investor confidence that began in late 2025 and rolled through the first half of this year.
Valuations that once looked untouchable have been cut in half, and sometimes even worse.
But reporting season arrives this month, and it may bring fresh growth catalysts with it.
Here are three ASX tech shares heading into August with something to prove.
Image source: Getty Images
Why ASX tech shares fell so hard
The sell-off was never really about earnings.
It was about what investors were willing to pay for growth, and renewed concerns about artificial intelligence disruption drove a heavy de-rating right across the sector.
Governance questions at individual companies made matters worse.
The result is a group of quality businesses trading well below their highs.
WiseTech Global (ASX: WTC)
WiseTech is the most extreme example.
The shares were changing hands around $33.88 in mid-July, down 71% over 12 months.
Yet brokers have not walked away.
The average 12-month price target sits near $63, implying almost 96% upside.
Bell Potter is more bullish still, holding a buy rating and a $71.75 target that would see the shares more than double from here.
The broker argued the stock "looks value on an FY27 EV/EBITDA multiple of c.15x".
Its CargoWise platform remains deeply embedded in global logistics networks, where switching costs are high and pricing power is strong.
Over the last 12 months, governance has been the core problem, but that is slowly being addressed.
Raelene Murphy was appointed independent chair in July, while founder Richard White stays on the board as an executive director and chief innovation officer.
WiseTech will report its FY26 result on 26 August.
Pro Medicus (ASX: PME)
Pro Medicus shares have fallen for a different reason.
This is a high-quality business that simply got very expensive. Pro Medicus shares were trading around $163.94 recently, roughly 50% below their high.
However, the company's demand drivers have not deteriorated.
Hospitals keep generating more scans, and radiologists continue to work working through larger image files.
That is because Pro Medicus' Visage software is best-in-class, helping clinical teams pull those images up quickly across health networks.
The company is now pushing beyond radiology into cardiology and digital pathology, and that expansion should widen its addressable market over the coming decade.
Pro Medicus reports on 18 August, although its valuation still demands strong execution, which remains the main risk with this one.
Global X Semiconductor ETF (ASX: SEMI)
To be clear, SEMI ETF is not a company.
Rather, SEMI ETF is an ASX-listed exchange-traded fund (ETF) that holds global semiconductor businesses.
It was the standout performer of the first half, rising almost 102% in the six months to June 2026.
The AI hardware trade has been extraordinarily strong offshore while local names were being sold down.
For investors who want exposure to tech shares without single-stock risk, an ETF spreads the bet across the supply chain, though the trade-off is concentration in one notoriously cyclical industry.
Foolish takeaway for ASX tech shares
Beaten-down tech names can rebound sharply, but they can also stay cheap for a very long time.
WiseTech still has to prove it can overcome its governance issues and hold onto its key customers.
Pro Medicus continues to trade on a premium multiple that leaves little room for error.
And SEMI ETF carries the volatility of a single global industry.
The upside case for all three is considerable, but so is the risk.
For long-term investors, this trade-off is worth thinking through carefully.
